Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

Research output: Contribution to journalArticlepeer-review


Large alternative donor pools provide the potential for selecting a different donor for a second allogeneic (allo) bone or marrow transplant (BMT). As HLA disparity may contribute to the graft-versus-tumor effect, utilizing new mismatched haplotype donors may potentially improve the antitumor activity for relapsed hematologic malignancies despite a previous alloBMT. Data from patients who received a second alloBMT for relapsed hematologic malignancies at Johns Hopkins were analyzed. Outcomes were compared between patients who received a second allograft with the same MHC composition and those who received an allograft with a new mismatched haplotype. Loss of heterozygosity analysis was performed for patients with acute myeloid leukemia (AML) whose first allograft was haploidentical. Between 2005 and 2015, 40 patients received a second BMT for a relapsed hematologic malignancy. The median follow-up is 750 (range, 26 to 2950) days. The median overall survival (OS) in the cohort is 928 days (95% confidence interval [CI], 602 to not reached [NR]); median event-free survival (EFS) for the cohort is 500 days (95% CI, 355 to NR). The 4-year OS is 40% (95% CI, 25% to 64%), and the 4-year EFS is 36% (95% CI, 24% to 55%). The cumulative incidence of nonrelapsed mortality by 2 years was 27% (95% CI, 13% to 42%). The cumulative incidence of grade 3 to 4 acute graft-versus-host disease (GVHD) at 100 days was 15% (95% CI, 4% to 26%); the cumulative incidence of extensive chronic GVHD at 2 years was 22% (95% CI, 9% to 36%). The median survival was 552 days (95% CI, 376 to 2950+) in the group who underwent transplantation with a second allograft that did not harbor a new mismatched haplotype, while it was not reached in the group whose allograft contained a new mismatched haplotype (hazard ratio [HR],.36; 95% CI,.14 to.9; P =.02). EFS was also longer in the group who received an allograft containing a new mismatched haplotype, (NR versus 401 days; HR,.50; 95% CI,.22 to 1.14; P =.09). Although the allograft for this patient's second BMT contained a new mismatched haplotype, AML nevertheless relapsed a second time. Second BMTs are feasible and provide a reasonable chance of long-term survival. An allograft with a new mismatched haplotype may improve outcomes after second BMTs for relapsed hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)1887-1894
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Issue number11
StatePublished - Nov 2017


  • HLA loss
  • Haploidentical
  • Post-transplant cyclophosphamide
  • Relapse
  • Second transplantations

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation'. Together they form a unique fingerprint.

Cite this